Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2019
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31Saranya Chumsri, Zhuo Li, Daniel J Serie, et al.Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.RMD Open|October 6, 2025
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trialPatrick G Gavin, Erik L Allman, David Jayne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.Clinical & Translational Immunology|January 25, 2021
An acetate-yielding diet imprints an immune and anti-microbial programme against enteric infectionYu Anne Yap, Keiran H McLeod, Craig I McKenzie, et al.Annals of the Rheumatic Diseases|April 3, 2024
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trialsTina Baker, Hoda Sharifian, Paul J Newcombe, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Machine Learning Predicts Oxaliplatin Benefit in Early Colon CancerLujia Chen, Ying Wang, Chunhui Cai, et al.Pageof 3